Pharmacogenomics

---

Emerging cancer models for drugs and novel dosages development

WCRJ 2022; 9: e2153
DOI: 10.32113/wcrj_20221_2153

Genotyping panel to assess Hand-Foot Syndrome in T2DM and cancer patients who receive concurrent Platin derivates and Biguanides

WCRJ 2020; 7: e1748
DOI: 10.32113/wcrj_202011_1748

Loop-mediated isothermal amplification (LAMP) and its variants as simple and cost effective for genotyping method

WCRJ 2018; 5 (3): e1116
DOI: 10.32113/wcrj_20189_1116

Costs and quality of genomics tests in the oncology field

WCRJ 2016; 3 (4): e801
DOI: 10.32113/wcrj_201612_801

A cost-effectiveness method for detection of ABL mutations in patients who developed Imatinib resistance

WCRJ 2016; 3 (4): e799
DOI: 10.32113/wcrj_201612_799

Evaluation of clinical and economic impact of pharmacogenomics testing in taxanes-based therapy

WCRJ 2016; 3 (3): e744

Genetic variants influencing vitamin K

WCRJ 2016; 3 (1): e649

Overview of FDA-approved anti cancer drugs used for targeted therapy

WCRJ 2015; 2 (3): e553

Clinically relevant of Cytochrome P450 Family enzymes for drug-drug interaction in anticancer therapy

WCRJ 2015; 2 (2): e524

Selected Pharmacogenetic panel test for toxicity prevention of drug-drug interactions between Highly Active Antiretroviral Therapy (HAART) and antiblastic chemotherapy

WCRJ 2015; 2 (1): e492

• 1
• 2
• Older